Abstract Pancreatic cancer is among the most lethal malignancies resistant to conventional therapies. The urgent need for new therapies has turned the spotlights on immunotherapy. In recent years, a growing body of evidence has already been gathered regarding the efficacy of genetic engineering modified T-cells, checkpoint inhibitors of T-cells, killer cells induced by dendritic cells and cytokine in patients with pancreatic cancer. Cryoimmunotherapy in situ and extra-tumor and immunotherapy combined with chemotherapy could also increase the effectiveness. Research of pancreatic cancer vaccine has made some progress. The immunity enhancing function of some traditional herbs have been reported, such as Ginsenoside Rg3, which could enhance T-cell subsets and NK cell activity in pancreatic cancer patients with chemotherapy.
展开▼
